KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker (NYSE: SYK), a global leader in medical technologies, announced the signing of a definitive agreement to acquire all of the issued and outstanding shares of Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures.

密歇根州卡拉马祖市——（商业新闻短讯）——全球医疗技术领导者Stryker（纽约证券交易所代码：SYK）宣布签署最终协议，收购Artelon的所有已发行和流通股，Artelon是一家私营公司，专门从事足踝部软组织固定产品和运动医学程序的创新。

The acquisition will strengthen Stryker’s offerings in the soft tissue fixation segment and highlights Stryker’s commitment to providing differentiated solutions for ligament and tendon reconstruction..

此次收购将加强史崔克在软组织固定领域的产品，并突显史崔克致力于为韧带和肌腱重建提供差异化解决方案。。

Artelon’s technologies complement and expand the current range of products available to Stryker’s foot and ankle and sports medicine specialist customers. Its differentiated synthetic technology is designed to enhance biological and mechanical ligament and tendon reconstruction, with over 60,000 implantations worldwide.

Artelon的技术补充并扩大了史崔克足踝部和运动医学专业客户现有的产品范围。其差异化的合成技术旨在增强生物和机械韧带和肌腱的重建，全球有60000多个植入物。

The acquisition will also allow Stryker to position itself more competitively in the foot and ankle and sports medicine segment with an innovative biomaterial technology that supports the healing of the patient’s soft tissues..

此次收购还将使史崔克凭借支持患者软组织愈合的创新生物材料技术，在足踝和运动医学领域更具竞争力。。

“Artelon’s proven product portfolio and differentiated offerings will enhance our ability to innovate and serve our customers,” said Tim Lanier, president of Stryker’s Trauma & Extremities division. “The addition of Artelon’s products to our already robust foot and ankle and sports medicine product portfolios will fuel our goal of establishing comprehensive offerings for customers in these segments.

史崔克创伤与四肢部总裁蒂姆·拉尼尔（TimLanier）表示：“Artelon久经考验的产品组合和差异化的产品将增强我们创新和服务客户的能力。”。“将Artelon的产品添加到我们已经强大的足踝和运动医学产品组合中，将推动我们为这些细分市场的客户建立全面产品的目标。

We share a common dedication to integrity, quality, and advancing the knowledge of healthcare providers to achieve the best clinical outcomes and rebuild patients’ lives.”.

我们共同致力于诚信，质量和提高医疗保健提供者的知识，以实现最佳的临床结果并重建患者的生活。”。

This transaction is subject to customary closing conditions. Stryker and Artelon will continue to operate as separate entities and proceed with business as usual until the transaction closes.

该交易受惯例成交条件的约束。Stryker和Artelon将继续作为单独的实体运营，并照常进行业务，直到交易结束。

About Stryker

关于史崔克

Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually.

史崔克是医疗技术领域的全球领导者，与客户一起致力于改善医疗保健。该公司在医学、神经技术、骨科和脊柱领域提供创新产品和服务，有助于改善患者和医疗保健结果。与世界各地的客户一起，史崔克每年影响超过1.5亿患者。

More information is available at www.stryker.com..

有关更多信息，请访问www.stryker.com。。